CGRP Inhibitors Transform Migraine Care Over 5 Years as 30% of Patients Experience Aura
Updated
Updated · The Guardian · Jul 19
CGRP Inhibitors Transform Migraine Care Over 5 Years as 30% of Patients Experience Aura
2 articles · Updated · The Guardian · Jul 19
Summary
Gepants and monthly CGRP monoclonal antibody injections have reshaped migraine treatment over the last four to five years by directly blocking the pain chemical now tied to attacks.
CGRP was identified as a key driver in the trigeminovascular system, replacing older vascular theories with a neurological model in which the trigeminal nerve triggers the brain’s pain network.
About 30% of sufferers experience aura, and migraines can unfold across four phases—from prodrome to postdrome—with pain lasting four to 72 hours and exhaustion lingering up to two days.
Migraine remains one of the WHO’s top 10 most disabling diseases globally, affecting women about twice as often as men and often disrupting work during prime adult years.
Access is still a major barrier: the newer drugs are costly, prescribing can be cumbersome, and specialists say more headache-trained clinicians are needed to get patients treated faster.
Science has solved the migraine puzzle, so why are patients still waiting years for effective treatment?
Are new 'miracle' migraine drugs hiding rare but serious side effects that could create a future health crisis?
A gene helped humans conquer the cold but now causes migraines. Is modern life turning our evolutionary strengths into weaknesses?
Migraine Prevention Breakthroughs: CGRP Inhibitors, Pediatric Expansion, and the Equity Gap in 2024
Overview
Migraine prevention is rapidly evolving due to the ongoing need to reduce the frequency, intensity, and disability of migraine attacks. Although about 40% of people with migraines could benefit from preventive treatment, many still find current first-line medicines ineffective or hard to tolerate. This unmet need has driven significant advancements, especially with the introduction of CGRP monoclonal antibodies, which have shown strong effectiveness and better tolerability. As a result, research and development in this area remain crucial, with the global migraine prevention market expected to grow substantially in the coming years.